Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
murine Interleukin-12 mRNA (mIL12 mRNA)
- Development stage
- Preclinical
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intratumoral Injection
01
Overview
mIL12 mRNA is an mRNA-based drug that encodes for murine Interleukin-12 (IL-12), a cytokine involved in the immune response. It is used intratumorally to induce anti-tumor immune responses by activating cytotoxic T cells and modulating the tumor microenvironment. The administration of mIL12 mRNA has shown effectiveness in murine tumor models by enhancing PD-L1 efficacy and promoting durable complete responses in checkpoint inhibitor-resistant tumors[1][2].
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on murine Interleukin-12 mRNA (mIL12 mRNA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on murine Interleukin-12 mRNA (mIL12 mRNA).